Drug-target interaction prediction is an important problem for the development of novel drugs and human medical improvement. Many supervised and semi-supervised methods are proposed to uncover the relation between drugs and targets. Under the hypothesis that similar drugs target similar target proteins and the framework of Random Walk with Restart, the method of Networkbased Random Walk with Re...

Most diseases result in metabolic changes. In many cases, these changes play a causative role in disease progression. By identifying pathological metabolic changes, metabolomics can point to potential new sites for therapeutic intervention. Particularly promising enzymatic targets are those that carry increased flux in the disease state. Definitive assessment of flux requires the use of isotope...

Generating new therapeutic hypotheses for human disease requires the analysis and interpretation of many different experimental datasets. Assembling a holistic picture of the current landscape of drug discovery activity remains a challenge, however, because of the lack of integration between biological, chemical and clinical resources. Although tools designed to tackle the interpretation of ind...

420 Thrombin-activatable fibrinolysis inhibitor (TAFI) is a 60kDa metallocarboxypeptidase produced by the liver and present in plasma. Independently discovered by several groups, the enzyme is also known as plasma procarboxypeptidase B, procarboxypeptidase R, or procarboxypeptidase U (1-5). TAFI as nomenclature was introduced by Bajar et al. (5). TAFI is expressed as a latent precursor requirin...

Specific delivery of therapeutic agents to solid tumors and their bioavailability at the target site are the most clinically important and challenging goals in cancer therapy. Liposomes are promising nanocarriers and have been well investigated for cancer therapy. In spite of preferred accumulation in tumors via the enhanced permeability and retention (EPR) effect, inefficient drug release at t...